... radionuclide therapy peptide receptor radionuclide therapy MIBG Lutathera tyrosine kinase inhibitor ACCEPTED MANUSCRIPT 1 Approach to the Patient with Metastatic Pheochromocytoma and Paraganglioma 2 Authors 3 Hussam Alkaissi, MD, MS1; David Taieb, MD, PhD2; Frank I. Lin, MD3; Jaydira Del Rivero, 4 MD4...

....0000000000001537 . 14. Weng   CD , Liu   KJ , Jin   S . et al.   Triple-targeted therapy of dabrafenib, trametinib, and osimertinib for the treatment of the acquired BRAF V600E mutation after progression on EGFR-tyrosine kinase inhibitors in advanced EGFR-mutated non-small cell lung cancer...

... between 2010 and 2022 were included in this study. Systemic therapy prior to surgery included agents including epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) in eight patients and non-TKI agents in six (chemotherapy alone: four, chemotherapy plus immune checkpoint inhibitors: two...

... pluripotent hematopoietic stem cells in the bone marrow. The introduction of tyrosine kinase inhibitors has significantly improved the survival rates of CML patients. This study aimed to identify immune-related genes associated with the response to imatinib (IM) therapy in CML. Gene expression profiles from...

... study, we examined 5-HT release by a set of anaplastic lymphoma kinase (ALK)/ROS1 tyrosine kinase inhibitors (TKIs) and epidermal growth factor receptor (EGFR) TKIs and compared their sensitivity with the frequency of clinically observed emesis. Commercially available chemicals and reagents were used...

... medium, provided the original work is properly cited. See the journal About page for additional terms. Abstract Tyrosine kinase inhibitors (TKIs) are being used more regularly in treatment regimens for pediatric cancers. They have distinct side effect profiles, including endocrinopathies. Here we...

... inhibitor leptomeningeal metastasis non-small cell lung cancer tyrosine kinase inhibitor KAKENHI 10.13039/501100001691 22K09272 Key Points EGFR mutation is a significant predictor of Type I leptomeningeal metastasis (LM). Osimertinib prolongs the time to Type I LM. Immune...

... World Data. Methods We analyzed the clinical data of consecutive patients with NSCLC receiving EGFR-tyrosine kinase inhibitors between April 2010 and March 2020 at 46 Tokushukai Medical Group hospitals in Japan. The patient’s insurance coverage status was extracted from electronic medical records...

... medium, provided the original work is properly cited. ABSTRACT Although adeno-to-squamous transition (AST) has been observed in association with resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) in clinic, its causality, molecular mechanism and overcoming strategies...

... fusions are an established oncogenic driver comprising 1%-2% of non–small cell lung cancer (NSCLC). Successful targeting of ROS1 fusion oncoprotein with oral small-molecule tyrosine kinase inhibitors (TKIs) has revolutionized the treatment landscape of metastatic ROS1 fusion-positive...

... re-use, please contact [email protected] Abstract Background An immune checkpoint inhibitor (ICI) backbone of either ICI doublet (ipilimumab-nivolumab [ipi-nivo]) or tyrosine kinase inhibitor (TKI) with ICI (such as axitinib-pembrolizumab [axi-pembro], cabozantinib-nivolumab [cabo-nivo...

... KEYNOTE-937 NCT03867084 Pembrolizumab (anti-PD-1 antibody) Placebo III RFS EMERALD-2 NCT03847428 Durvalumab and/or bevacizumab Durvalumab III RFS TKI, tyrosine kinase inhibitor; OS, overall survival; PFS, progression-free survival; ORR, objective response rate; TACE, transarterial...

... of tirabrutinib, a second-generation Bruton’s tyrosine kinase inhibitor, for relapsed/refractory primary central nervous system lymphoma (PCNSL). Here, we report the long-term efficacy and safety after a 3-year follow-up. Methods Eligible patients were aged ≥ 20 years with histologically diagnosed PCNSL...

... in Neuro-Oncology criteria and disease stabilization was seen in 3 patients (14.3%). Conclusions Afatinib taken orally was safe and well-tolerated up to 280 mg every 7 days in brain cancer patients. Afatinib brain cancer ErbB EGFR tyrosine kinase inhibitor Key Points Oral afatinib 280 mg every...

...) and provides data to guide sequencing of therapies and patient selection for treatment with tivozanib in the current RCC treatment paradigm. renal cell carcinoma tivozanib tyrosine kinase inhibitor VEGF blockade sequencing MDACC P30 CA016672 Andrew Sabin Family Foundation 10.13039/100012287...

... is the most prominent character and a poor prognostic factor of advanced HCC. ^{3 , 4} Systemic therapy, such as tyrosine kinase inhibitors (TKIs) and anti-PD-1 antibodies, forms the cornerstone of treatment for advanced HCC. Conversion therapy is aimed to downstage initially unresectable tumors...

...:https://dbpia.nl.go.kr/pages/standard-publication-reuse-rights ) Abstract Objective The introduction of new-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) has afforded promising overall survival outcomes in clinical trials for non-small-cell lung cancer. We aim to investigate...

... Purpose Ibrutinib is a Bruton’s tyrosine kinase inhibitor used to treat multiple hematologic malignancies and graft-versus-host disease. Though less myelosuppressive than cytotoxic chemotherapy, increased infections, including invasive fungal infections (IFIs), have been reported with ibrutinib use...

... of METdriven status is 35 40% in PRCC. Savolitinib is an oral, potent and highly selective MET tyrosine-kinase inhibitor (TKI) demonstrating preliminary clinical activity in advanced solid tumors, including in MET-driven PRCC, defined as presence of any of the following molecular alterations, in the absence...

... significance was defined as P < 0.05. All analyses were conducted by using JMP software (version 15; SAS Institute Inc., Cary, NC, USA). MET AXL immunotherapy tyrosine kinase inhibitor molecular-targeted therapy kidney cancer Cabozantinib is an oral, small-molecule tyrosine kinase inhibitor...